Ultragenyx Pharmaceutical | RARE - Ebit

Aktienkurs
25.00
Täglich Wechseln
-0.80 -3.10%
Monatlich
1.96%
Jährlich
-29.80%
Q2 Prognose
24.50




Ebit Veränderung Datum
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Immunic USD -23.33M 2.67M 2025-12
Insmed USD -200.28M 49.43M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Karyopharm Therapeutics USD -17.84M 8.44M 2025-12
Kyowa Hakko Kirin JPY 9.52B 28.83B 2026-03
MacroGenics USD -12.1M 32.26M 2025-12
Moderna USD -1.39B 531M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD -2.2M 11.41M 2024-06
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03
Xoma USD -10.08M 4.4M 2024-06